How to invest in the science of longer life without turning your retirement portfolio into a medical experiment.

Imagine scientists discover how to slow aging. Artificial intelligence (AI) helps identify promising drugs, billionaires fund the laboratories, and humanity gets a shot at living healthier for longer.

Fantastic! Now imagine buying a tiny biotech stock at the top, watching it fall 70%, and spending your retirement refreshing clinical-trial updates. Congratulations: you may live longer, but your investment thesis is on life support. 🤕

Anthropic CEO Dario Amodei has speculated that powerful AI could compress 50–100 years of biological progress into 5–10 years. He even discusses the possibility of doubling human lifespan. That is an ambitious forecast—not a scientific guarantee or an investment timetable. [1]

Here is the more useful question: If AI accelerates longevity research, who gets paid—and who gets left holding the laboratory bill?

1. Three layers, three very different bets

Think of longevity investing as a gold rush. You can sell the shovels, provide the services, or dig for gold yourself. Only one of those requires finding the gold.

NVDA: The AI powerhouse. NVIDIA's BioNeMo platform supports AI-driven drug discovery, including molecular generation and protein modelling. But NVIDIA is not a longevity pure-play: its business depends on many AI markets. Longevity is potential upside, not the entire investment case. [2]

SDGR: The computational chemistry specialist. Schrödinger combines scientific software with its own drug-discovery programmes. In 2025, it generated $255.9 million in revenue but recorded a $103.3 million net loss. Its software business is attractive to investigate; its losses remind us that a promising platform still needs a path to sustainable profitability. [3]

IQV: The clinical-trial service provider. IQVIA supplies clinical research services, healthcare data and analytics. Drug developers still need patients, trial management and evidence—even when AI speeds up early research. The catch: IQVIA is a broad healthcare-services business, not a direct bet on reversing aging.

CRSP and RXRX: The moonshots. CRISPR Therapeutics develops gene-based medicines; Recursion combines computational and biological approaches to drug discovery. Both offer scientific optionality, but neither is a proven longevity investment. CRSP's approved CASGEVY therapy treats specific blood disorders, not aging. Recursion's 2025 operating loss was roughly $648 million—an expensive reminder that scientific ambition consumes real cash. [4]

And those famous private longevity companies? You cannot buy their shares directly through an ordinary stock-market order. A fascinating private laboratory is not automatically an available public investment.

2. The biggest trap: faster discovery does not mean faster profits

AI can help scientists identify molecules, predict properties and prioritise experiments. It cannot guarantee a safe, effective drug that regulators approve and patients can access.

A 2024 analysis by Jayatunga and colleagues found encouraging early results for AI-discovered medicines: estimated Phase I trial success rates were 80–90%, while Phase II success was around 40%. The researchers noted the limited sample size. In other words, AI may improve the starting point; it has not abolished clinical failure. [5]

Longevity also faces a regulatory hurdle. There is no straightforward, established US Food and Drug Administration (FDA) approval route for a medicine whose sole indication is reversing aging. Developers generally need evidence for specific diseases or conditions.

The weak point is the gap between scientific progress and shareholder returns. A discovery can be revolutionary and still be a lousy investment if the company runs out of cash, faces competition or was purchased at an absurd valuation.

3. ETFs: diversify before you speculate

For retail investors, exchange-traded funds (ETFs)—baskets of securities traded like shares—can reduce the risk of betting on one company.

Fees are based on published fund information and should be rechecked before investing. [6]

My practical ranking is VTI first as a possible core, XLV for broader healthcare exposure, then IBB or XBI for a deliberate biotech satellite. This is a ranking by portfolio role—not a forecast of returns.

SMH, the semiconductor ETF, is a possible AI-infrastructure investment, but not a longevity fund. ARKG and WDNA offer more thematic exposure, yet their concentration, fees and holdings deserve scrutiny. None deserves an automatic place in your portfolio just because its name sounds futuristic.

4. The retail investor's survival checklist

Before buying any stock with “AI,” “genomics” or “longevity” in its pitch deck, ask:

• Is AI genuinely material? Does the company sell useful tools or demonstrate real research progress—or merely sprinkle “AI” over a presentation?
• Is there a business today? Check recurring revenue, customer demand, margins and cash flow.
• Can it survive? For speculative biotech, examine cash runway, spending and potential share dilution.
• What evidence exists? Review clinical-trial phases, safety signals, partnerships and the next major milestone.
• What is already priced in? A brilliant company can still be a terrible purchase at an inflated valuation.
• What would prove me wrong? Write down the evidence that would invalidate your thesis before buying.
• Can I withstand a 50–80% drawdown? If not, use broader diversification or skip the speculative stock.

Do not apply profitable-company metrics blindly to pre-revenue biotech. Earnings per share and free-cash-flow margins may be negative for years. For these businesses, cash runway, dilution and clinical evidence become the first survival tests.

A simple action plan

1. Build your diversified core before chasing a theme.
2. Check existing holdings to avoid accidentally doubling up on AI or healthcare exposure.
3. Consider a small speculative allocation—1–3% of the total portfolio is an example, not a universal rule—only if you can afford the loss.
4. Review results and cash runway after each major filing or clinical milestone.
5. Rebalance to your written risk limit; never increase a position merely to rescue a losing thesis.

Money needed within three years generally has no business being in speculative biotech. Clinical news can cause overnight price gaps, and stop-loss orders cannot guarantee your exit price.

5. The second-order twist: a longer life needs a longer financial plan

If AI improves healthspan—the years lived in good health—it could reshape healthcare, consumption, work and retirement. But living longer may also mean funding more years of living expenses.

The irony? You might get the scientific breakthrough you wanted, only to discover that your retirement savings were designed for a much shorter sequel. 💸

So invest in the possibility of better medicine, but don't make your financial future dependent on it. Build wealth that can survive whether the breakthrough arrives next year, in twenty years, or never.

Health. Wealth. Wisdom.

#LongevityInvesting #AIStocks #BiotechInvesting #ETFInvesting #WealthBuilder #InvestWithEvidence

Wealth Builder: turn information overload into a plan

Every investor faces the same three traps: information overload, fear of missing out (FOMO), and underestimating risk. One headline promises immortality; another predicts a biotech crash. Which deserves your money—and which deserves a polite eye-roll?

Wealth Builder aims to turn noisy financial themes into practical frameworks: what is established, what is speculative, what to investigate, and how to manage risk. Passive-income and investing newsletters can also help you focus on sustainable cash flow, disciplined saving and long-term compounding instead of chasing every fashionable stock.

You do not need another hundred hot tips. You need clearer thinking and ideas you can test. Explore more like-minded newsletters here and find perspectives that help you build wealth with purpose—not panic. Your future self deserves better than a portfolio powered by FOMO. 😉

Notes and sources

1. Dario Amodei, Machines of Loving Grace (October 2024). His accelerated-biology timeline and lifespan discussion are forecasts, not established outcomes. Read the essay
2. NVIDIA, official BioNeMo platform information. BioNeMo​
3. Schrödinger, 2025 Form 10-K and financial results. SEC filing​
4. Recursion Pharmaceuticals, 2025 Form 10-K; CRISPR Therapeutics, second-quarter 2026 results and CASGEVY description. Recursion SEC filing · CRISPR Therapeutics results​
5. Jayatunga et al., “How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons,” Drug Discovery Today (2024). PubMed​
6. Official ETF pages: VTI, XLV, IBB, XBI.

Abbreviations: AI = artificial intelligence; ETF = exchange-traded fund; FDA = US Food and Drug Administration; Phase I/II = early stages of human clinical testing; FOMO = fear of missing out; cash runway = estimated time a company can fund operations with available cash.

This newsletter is educational, not individual financial advice. Prices, valuations, holdings and fees change. Verify the latest company filings and fund documents before investing.